PrimeGen US

Executive Summary

PrimeGen US is a private biotechnology company pioneering stem cell-based regenerative therapies for inflammatory diseases, with an initial focus on liver conditions such as NAFLD, NASH, and cirrhosis. The company's proprietary StemXcell™ platform activates mesenchymal stem cells (MSCs) to achieve targeted immunomodulation, addressing key drivers of hepatic inflammation and fibrosis. Founded in 2005 and based in Irvine, California, PrimeGen has maintained a low public profile and has not disclosed funding rounds or clinical stage. Its pipeline appears to be in preclinical or early clinical development, leveraging the established safety profile of MSCs while aiming for differentiated efficacy through platform-driven activation.

Upcoming Catalysts (preview)

• Q3 2026Preclinical proof-of-concept data for NASH program60% success
• TBDStrategic partnership or licensing deal for StemXcell platform40% success
• Q4 2026Series A or B financing round to advance lead candidate to IND50% success